CSPC PHARMA (01093) announced that its new chemical drug category 1 product, SYH2059 inhalation powder, has received approval from the U.S. Food and Drug Administration (FDA) to commence clinical trials in the United States. This product is a novel, highly active, and highly selective phosphodiesterase-4B (PDE4B) inhibitor with full independent intellectual property rights developed by the group. The approved formulation for clinical trials is an inhalation powder. Preclinical studies have demonstrated that the product significantly increases drug concentration in the lungs while reducing systemic exposure, thereby minimizing gastrointestinal side effects. In disease animal models, the product's efficacy was notably superior to existing medications, and it exhibited favorable pharmacokinetic properties and a high safety margin. The approved clinical indication is pulmonary fibrosis (PF), including idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). Currently, there are limited treatment options available for this disease, and patient benefits from existing therapies are constrained. This product has the potential to become an effective treatment for such conditions, holding significant clinical development value. The approval for clinical trials represents a major achievement for the group's advanced innovative inhalation technology platform and lays a solid foundation for the development of subsequent innovative inhalation formulations within its pipeline.